BioCentury on BioBusiness,
Product Discovery & Development
How in vitro tox presaged Bristol-Myers' costly failure with Inhibitex HCV drug
Inhibitex's Tox
By Michael Flanagan
Senior Writer
Published on
Monday, September 10, 2012
Bristol-Myers
Squibb Co. may have looked past in vitro safety signals in a
rush to add Inhibitex Inc.'s nucleoside NS5B polymerase inhibitor to its HCV portfolio.
If the pharma was gambling that it could find a therapeutic window for
BMS-986094 as it had previously done with blockbuster entecavir in HBV, the bet
backfired.
In August, BMS first suspended
and then terminated development of BMS-986094 after nine patients in a Phase II
trial were hospitalized with heart and kidney toxicities, including one patient
who died of heart failure.
87
words displayed of
2280
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]